Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioMe Oxford is a medical technology company spun out from the University of Oxford that focuses on transforming gut health through precision microbiome sampling. The company has developed a proprietary ingestible smart capsule designed to capture high-quality, site-specific samples from the small intestine, which is otherwise difficult to access non-invasively. This technology aims to replace invasive endoscopic procedures and provide more accurate data for the diagnosis and treatment of gastrointestinal and metabolic diseases. By enabling large-scale microbiome profiling, BioMe Oxford supports drug development and personalized nutrition strategies. The device is designed to trigger at specific locations in the GI tract to ensure the integrity of the microbial community being sampled, addressing the limitations of stool-based analysis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioMe Oxford.